A few years later, the AAV2-NGF Study Team [198] tested if the stereotactically guided intracerebral injection of AAV2-NGF was well tolerated and exhibited preliminary evidence of impact on cognitive decline, with encouraging results regarding safety, but no positive results were obtained on clinical outcomes or selected AD biomarkers. This evidence concerns the gene NGF and Alzheimer disease.